

# May 2009 Clinical Trials Update

**By Jim Hughes**

LRG Clinical Trials Coordinator

## **Infinity IPI-504 Phase 3 RING trial in resistant GIST terminated:**

Infinity Pharmaceuticals Inc. announced April 15 that it had elected to terminate the IPI-504 phase 3 RING trial in resistant GIST upon the recommendation of its independent data monitoring committee (IDMC). The IDMC's recommendation to halt the trial was based on an early review of safety data from the first 46 patients enrolled in the study, which showed a higher than anticipated mortality rate among patients enrolled in the treatment arm. Infinity also announced that patients participating in the trial would no longer receive IPI-504. The

Life Raft Group continues to explore the options available for RING trial participants and will report additional details as they are available and can be verified.

Patients who participated in (or were planning on entering) the RING trial and are now seeking options can call the LRG office at 973-837-9092 or email us at [liferaft@liferaftgroup.org](mailto:liferaft@liferaftgroup.org)

## **Novartis Imatinib or Nilotinib Phase 3 first line advanced GIST now recruiting in US:**

This is a large international trial designed to ascertain if nilotinib is a better therapy for newly diagnosed advanced GIST patients. GIST patients who have not received prior TKI (tyrosine kinase inhibitor) therapy will be randomly assigned to receive either imatinib or nilotinib. The primary goal is to determine progression-free survival in both groups. Sites are now open in Southern California (City of Hope), Austria, Canada, Spain and Thailand. This trial plans to accrue over 700 participants in North and South America, Europe, Africa and South-East Asia. And will be collecting data for over ten years.

## **Astex Therapeutics AT13387 Phase 1 HSP-90 inhibitor added for resistant solid tumors:**

This phase 1 trial is designed to determine the maximum tolerable dose and the safety of AT13387. AT13387 is a small molecule HSP-90 inhibitor. It differs from IPI-504 in that it was designed specifically for HSP-90 inhibition. IPI-504 is a soluble refinement of the drug 17-AAG which in turn is a synthetic form of the antibiotic Geldanamycin. Geldanamycin has HSP-90 inhibition properties but also exhibits hepatotoxic-

ity. Astex describes their fragmented drug design platform which they claim uses as starting points very small, low molecular weight, drug fragments. Astex asserts that these fragments have the potential to keep the overall complexity and molecular weight of each drug candidate low. Astex also claims that this results in "high ligand efficiency" and "results in drug candidates having lower molecular weight, reduced metabolic liability, improved target selectivity and ease of chemical synthesis." This trial is running at three closely related centers in the Longwood medical area of Boston. The Principal Investigator is Geoffrey Shapiro, MD, PhD and Director of the Early Drug Development Center at Dana Farber Cancer Institute (DFCI) a position similar to George Demetri's at the Sarcoma Center. We are publishing all contact information but would suggest contacting Dana-Farber first and coordinating participation with the Sarcoma Center.

## **"Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST" at MD Anderson:**

This Phase 2 trial has stopped recruiting new patients and is now ongoing.

## **Mt Sinai School of Medicine Added Sunitinib & Stereotatic Radiation Phase 2:**

This trial will accept GIST patients. It is similar to a trial now running in Helsinki, Finland and another in Australia. Historically, GIST tumors have not responded to radiotherapy. Concurrent TKI therapy and the advent of newer radiation technologies may open the pos-

## The Life Raft Group

Who are we, what do we do?

**The Life Raft Group (LRG) directs research to find a cure for a rare cancer and help those affected through support and advocacy until we do.**

The LRG provides support, information and assistance to patients and families with Gastrointestinal Stromal Tumor (GIST). The LRG achieves this by providing an online community for patients and caregivers, supporting local in-person meetings, patient education through monthly newsletters and webcasts, one-on-one patient consultations, and most importantly, managing a major research project to find the cure for GIST.

### Disclaimer

We are patients and caregivers, not doctors. Information shared is not a substitute for discussion with your doctor. For the very latest information, see the LRG Clinical Trials database at: [http://liferaftgroup.org/treat\\_trials.html](http://liferaftgroup.org/treat_trials.html).

From Page 1

sibility of effectively treating selected tumors with radiation. This trial targets “oligometastatic disease”. “Oligo” is a prefix meaning roughly “a few”. A recent retrospective of 12 GIST patients treated with radiation therapy at the Royal Marsden in London was presented at the 2008 Connective Tissue Oncology Society (CTOS) conference. The poster

concluded that “A dose of 30 Gy in 10# given over 2 weeks appears to give effective, durable symptom control with minimal toxicity and should be considered for selected patients with this diagnosis (GIST).”

**Novartis Nilotinib Phase 2 Japan for resistant GIST:**

This trial is ongoing and no longer recruiting participants.


**Southwest Oncology Group (SWOG)**

**Phase 3 Imatinib & Bevacizumab first line for advanced GIST:**

We have added nine major cancer center sites currently recruiting to this listing. This trial adds and changes sites almost daily. Multiple Community Clinical Oncology Program (CCOP) sites are available across the United States. We have chosen to list the CCOP regional contact points and those major centers outside the CCOP. For complete site detail please visit the [clinicaltrials.gov](http://clinicaltrials.gov) website and search for NCT00324987.


**First Line Options for Advanced GIST**

Figure 1: United States



Figures 1 and 2 represent an overview of first-line options for advanced GIST in the United States and internationally.

Figure 2: International



First line trials represent a new opportunity for GIST patients to try to improve on their initial treatment.

### Options for Resistant GIST

Figure 3: United States





Figure 4: International



Figures 3 and 4 provide an overview of the available clinical trial options for Gleevec resistant GIST. Some trials require resistance to Sutent as well.

Check the actual trial listing for details about eligibility. Several trials are for patients that are resistant to 400 mg of Gleevec but have not yet tried 800 mg.

Don't forget to check out the LRG Newsletter at [www.gistnews.org](http://www.gistnews.org) for the most up-to-date information on GIST research, advocacy issues and the GIST community.

Note: Trials are first grouped together by treatment phase. For example, the first grouping lists 2 trials that are open to patients in all treatment stages. Each trial description also lists the treatment stage under the "Stage" heading. Trials that are specifically for GIST are listed first. Trials are then sorted by phase in descending order) and then by drug name. Trial sites are sorted by country, state and then city.

**Treatment Stage:**  
**All**

**Imatinib**

*Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor*

Phase: 2  
 Stage: All  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT/PDGFR inhibitor  
 Strategy: Block KIT  
 NCT #: [NCT00764595](#)  
 Contact: Tatsuo Kanda, MD  
 Niigata University Medical and Dental Hospital  
 81-25-227-2228  
**Niigata University Medical and Dental School**  
 Niigata, Japan  
 81-25-227-2228  
 Tatsuo Kanda, MD

**Surgery**

*Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor*

Phase: 2  
 Stage: All  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: Surgery  
 Strategy: Surgery  
 NCT #: [NCT00769782](#)  
 Contact: Tatsuo Kanda, MD  
 Niigata University Medical and Dental Hospital  
 81-25-227-2228  
**Niigata University Medical and Dental School**  
 Niigata, Japan  
 81-25-227-2228  
 Tatsuo Kanda, MD

**Treatment Stage:**  
**First-line**

**Imatinib + Bevacizumab**

*Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor*

Phase: 3  
 Stage: First-line  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT/PDGFR inhibitor+ VEGF inhibitor (antibody)  
 Strategy: Block KIT  
 Block tumor blood vessel growth  
 NCT #: [NCT00324987](#)  
 Contact: See each trial site.

**USC/Norris Comprehensive Cancer Center**  
 Los Angeles, CA USA  
 Clinical Trials Office  
 323-865-0451

**Lombardi CCC at Georgetown University**  
 Washington, DC USA  
 Clinical Trials Office  
 202-444-0381

**Iowa Oncology Research Association - CCOP**  
 Des Moines, IA USA  
 515-244-7586  
 Roscoe F. Morton, MD

**Carle Cancer Center - CCOP**  
 Urbana, IL USA  
 217-383-3394  
 Kendrith Rowland, MD

**University of Chicago**  
 Chicago, IL USA  
 Clinical Trials Office, 773-834-7424  
 Hedy Kindler, MD

**Wichita - CCOP**  
 Wichita, KS USA  
 316-262-4467  
 Shaker R. Dakhil, MD

**Kalamazoo - CCOP**  
 Kalamazoo, MI USA  
 269-373-7458  
 Raymond S. Lord, MD

**Metro Minnesota - CCOP**  
 St. Louis Park, MN USA  
 592-993-1517  
 Patrick J. Flynn, MD

**Ozarks Regional - CCOP**  
 Springfield, MO USA  
 417-269-4520  
 John W. Goodwin, MD

**University of Mississippi Cancer Clinic**  
 Jackson, MS USA  
 Robert D. Hamilton  
 601-984-5590

**Montana Cancer Consortium - CCOP**  
 Billings, MT USA  
 406-238-6290  
 Benjamin Marchello, MD

**Southeast Cancer Control Consortium - CCOP**  
 Winston-Salem, NC USA  
 910-777-3036  
 James M. Atkins, MD

**University of New Mexico**  
 Albuquerque, NM USA  
 Clinical Trials Office  
 505-272-6972

**Syracuse Hematology-Oncology Associate of Central New York - CCOP**  
 East Syracuse, NY USA  
 315-472-7504  
 Jeffrey J. Kirshner, MD

**Roswell Park Cancer Institute**  
 Buffalo, NY USA  
 Clinical Trials Office  
 877-275-7724

**Dayton Clinical Oncology Program - CCOP**  
 Kettering, OH USA  
 937-395-8678  
 Howard M Gross, MD

**Toledo Community  
Hospital Oncology - CCOP**  
Toledo, OH USA  
419-255-5433  
Paul L. Schaefer, MD

**Columbus - CCOP**  
Columbus, OH USA  
614-443-2267  
Philip J. Kuebler, MD

**Cleveland Clinic Taussig  
Cancer Center**  
Cleveland, OH USA  
Clinical Trials Office  
866-223-8100

**Columbia River Oncology  
Program - CCOP**  
Portland, OR USA  
503-216-6260  
Keith Larimer, MD

**Knight Cancer Institute at  
Oregon Health Sciences  
University (OHSU)**  
Portland, OR USA  
503 494-6594  
Michael Heinrich, MD

**Geisinger Clinical &  
Medical Center - CCOP**  
Danville, PA USA  
570-271-6413  
Albert M. Bernath, MD

**Fox Chase Cancer Center**  
Philadelphia, PA USA  
1-888-FOX-CHASE  
Margaret von Mehren, M.D.

**Gibbs Regional Cancer  
Center - CCOP**  
Spartanburg, SC USA  
864-560-7050  
James Bearden, III, MD

**Cancer Therapy and  
Research Center**  
San Antonio, TX USA  
Clinical Trials Office  
210-616-5798

**University of Texas Health  
Science Center**  
San Antonio, TX USA  
Dorothy Nguyen  
210-567-4777

**Fred Hutchinson Cancer  
Research Center**  
Seattle, WA USA  
206-386-2441  
Saul E. Rivkin, MD

**Marshfield Medical  
Research & Education  
Foundation**  
Marshfield, WI USA  
715-387-5426  
Mohammad Q. Khan, MD,  
FACP

---

## Masitinib, (AB1010)

*Efficacy and Safety of Masitinib  
(AB1010) in Comparison to Imatinib  
in Patients With Gastro-Intestinal  
Stromal Tumour*

---

Phase: 3  
Stage: First-line  
Conditions: Gastrointestinal Stromal  
Tumor  
Drug Type: KIT/PDGFR inhibitor  
Strategy: Block KIT  
NCT #: [NCT00812240](https://clinicaltrials.gov/ct2/show/study/NCT00812240)  
Contact: Antoine Adenis, M.D.  
+33 (0)3 20 29 59 59  
[a-adenis@o-lambret.fr](mailto:a-adenis@o-lambret.fr)

**Centre Oscar Lambret -  
Lille**  
Lille, France  
Antoine Adenis, MD

**Centre Leon Berard**  
Lyon, France  
+33607507064  
[blay@lyon.fnclcc.fr](mailto:blay@lyon.fnclcc.fr)  
Jean Yves-Blay, MD, PhD

**Centre Georges Francois  
Leclerc**  
Dijon, France

**Hopital Charles Nicolle**  
Rouen, France

**Centre Hospitalier Victor  
Jousselin**  
Dreux, France

**Centre Rene Huguenin**  
Saint-Cloud, France

**Centre Rene Gauducheau**  
Nantes, France

**Hopital Jean Minjoz**  
Besancon, France

**Institut Paoli Calmette**  
Marseilles, France  
Patrice Viens, MD, PhD

**Centre Val d'Aurele**  
Montpellier, France

**Hopital de la Source**  
Orleans, France

**Hopital Europeen Georges  
Pompidou**  
Paris, France

**Institut Bergonie**  
Bordeaux, France  
Binh Bui Nguyen, MD

**Hopital Robert Debre**  
Reims, France

**Hopital Saint-Georges**  
Beirut, Lebanon

**Hopital Saint-Joseph**  
Dora, Lebanon

**Middle East Institute of  
Health**  
Bsalm, Lebanon

**Hamoud Hospital**  
Saïda, Lebanon

**American University  
Hospital**  
Beirut, Lebanon

**MD Anderson - Orlando**  
Orlando, FL USA  
Clinical Trials Office - M.D.  
Anderson Cancer Center,  
713-792-3245  
Jon Trent, MD, PhD

**Henry Ford Health System**  
Detroit, MI USA

**Beth Israel Medical Center**  
New York, NY USA



**Nilotinib or Imatinib**

*Phase III, Open-Label Study of  
Nilotinib Versus Imatinib in GIST  
Patients*

Phase: 3  
Stage: First-line  
Conditions: Gastrointestinal Stromal  
Tumor  
Drug Type: KIT/PDGFRA inhibitor  
Strategy: Block KIT  
NCT #: **NCT00785785**  
Contact: Novartis Pharmaceuticals  
+1-800-340-6843

**National Cancer center  
Hospital East**  
Chiba, Japan  
Toshihiko Doi, MD  
+81-4-7133-1111  
tdoi@east.ncc.go.jp  
Toshihiko Doi, MD

**Shizuoka Cancer Center**  
Shizuoka, Japan  
Yusuke Onozawa  
+81-55-989-5222  
y.onozawa@scchr.jp  
Yusuke Onozawa, MD

**Aichi Cancer center  
Hospital**  
Aichi, Japan  
Ando Rie  
+81-52-762-6111  
jutaku\_a@aichi-cc.jp  
Akira Sawaki, MD

**Hokkaido University  
Hospital**  
Hokkaido, Japan  
Yoshito Komatsu  
+81-11-706-5657  
Yoshito Komatsu, MD

**National Cancer Center**  
Singapore, Singapore  
Simon Ong, MD  
+65 6436 8000  
Simon Ong, MD

**The Cancer  
Institute/National  
University Hospital**  
Singapore, Singapore  
Yong W. Peng, MD  
+65 6772 4670  
wei\_peng\_yong@nuh.com.sg  
Yong W. Peng, MD

**GVI Oncology**  
Panorama, South Africa  
J. C. Hanekom  
+27-21-930-7602  
jc.hanekom@cancercare.co.za  
J. I. Raats, MD

**Univerity of Pretoria**  
Pretoria, South Africa  
L. M. Dreosti, MD  
+27-012-354-1054  
L. M. Dreosti, MD

**University Hospital La Paz**  
Madrid, Spain  
Cristobal Belda-Iniesta, MD  
34-1-2071138  
cbelda.hulp@salud.madrid.org  
Cristobal Belda-Iniesta, MD

**Consorci Hospitalari Parc  
Tauli**  
Barcelona, Spain  
Jose G. Ruiz  
+34-937-242-579  
jgarciar@tauli.cat  
Charles Pericay, MD

**Chulalongkorn University**  
Bangkok, Thailand  
Virote Sriurnpong, MD  
+66-2-256-4533  
vsmtcu40@gmail.com  
Virote Sriurnpong, MD

**Prince of Songkla  
University**  
Songkla, Thailand  
Patrapim Sunpaweravong,  
MD  
+66-74-451-469  
spatrapi@medicine.psu.ac.th  
Patrapim Sunpaweravong,  
MD

**Khon Kaen University**  
Khon Kaen, Thailand  
O-Tur Saeseow, MD  
+66-43-366-569  
otur2000@yahoo.com  
O-Tur Saeseow, MD

**Siriraj Hospital**  
Bangkok, Thailand  
Vichien Srimuninnimit, MD  
+66-2-419-4488  
vsrimuninnimit@gmail.com

Vichien Srimuninnimit, MD  
**Universitätsklinik f. Innere  
Medizin**  
Vienna, Austria  
Thomas Brodowicz, MD  
+43-40400-4466  
Thomas Brodowicz, MD

**Site name unknown, Sao  
Paulo**  
Sao Paulo/SP, Brazil

**Site name unknown,  
Uberlandia**  
Uberlandia/MG, Brazil

**Oncologos del Occidente S.  
A.**  
Pareira, Colombia  
Paula Londono, MD  
+57-6-3310712  
palodelosrios@gmail.com  
Gustavo Rojas, MD

**Fundacion Santa Fe  
Bogota**  
Bogota, Colombia  
Natalia Arango, MD  
+57-1-5207787  
natiarang@hotmail.com  
Carlos Vargas, MD

**Oncomedica S.A./Intituo  
Medico de Alta Tecnologia**  
Monteria, Colombia  
Sandra Aruachan, MD  
+57-4-7854344  
sandra.aruachan@gmail.com  
Manuel Gonzalez, MD

**Birmingham Heartlands  
Hospital**  
Birmingham, UK  
James Whitehouse  
+44-0121-424-2187  
james.whitehouse@heartofengland.nhs.uk  
Ian Geh, MD

**Royal Marsden Hospital**  
London, UK  
Ian Judson  
+44-207-808-2200  
Ian Judson, MD

**Beatson West of Scotland  
Cancer Centre**  
Glasgow, UK  
Jeff White, MD  
011-0141-3017060  
jeff.white@ggc.scot.nhs.uk  
Jeff White, MD

**Arhus University Hospital**  
Arhus, Denmark  
Malene Bendix  
+45-8949-2683  
malebend@rm.dk  
Akmal Safwat, MD

**Hematology Oncology Services of Arkansas**  
 Little Rock, AR USA  
 Priscilla Gray  
 501-320-3217  
 Priscilla.Gray@hosaoa.com  
 Joanna Tucker  
 501 907 6444  
 Joanna.Tucker@hosaoa.com  
 Brad Baltz, MD

**City of Hope**  
 Duarte, CA USA  
 Neeti Arora  
 626-256-4673 xt 63019  
 narora@coh.org  
 Warren Chow, MD

**City of Hope - Pasadena**  
 Pasadena, CA USA  
 Doni Woo, RN  
 626-396-2900  
 Mark McNamara, MD

**Stanford Cancer Center**  
 Palo Alto, CA USA  
 Diane Ayala  
 650-725-9057  
 dayala1@stanford.edu  
 George A. Fisher, MD

**Moore's Cancer Center/UCSD Medical center**  
 La Jolla, CA USA  
 Sue A Castro  
 858-822-5353  
 scastro@ucsd.edu  
 Tony Reid, MD

**UCLA's Jonsson Comprehensive Cancer Center**  
 Los Angeles, CA USA  
 Natalie Chorn  
 Nchorn@mednet.ucla.edu  
 J. Randolph Hecht

**University of Colorado**  
 Aurora, CO USA  
 Heather Hallman  
 720-848-0678  
 Heather.hallman@ucdenver.edu  
 Anthony D. Elias, MD

**Mary Potter Oncology Center**  
 Pretoria, Gauteng South Africa  
 Erika Bosch  
 +27-12-346-6701  
 ericka.bosch@mpoc.co.za  
 G. L. Cohen, MD

**Sandton Oncology Centre**  
 Johannesburg, Gauteng  
 South Africa

**Robert Lurie Comp. Cancer Center Northwestern University Hospital**  
 Chicago, IL USA  
 Christopher Curtin  
 312-695-1331  
 c-curtin@northwestern.edu  
 Drashti Desai  
 312-695-1378  
 Mark Agulnik, MD

**University of Kansas Cancer Center**  
 Westwood, KS USA  
 Christopher Baierl  
 913-588-4721  
 cbaierl@kumc.edu  
 Margaret Hapgood  
 913-588-2566  
 mhapgood@kumc.edu  
 Stephen Williamson, MD

**Dana Farber Cancer Institute**  
 Boston, MA USA  
 George Demetri, MD  
 617-632-3985  
 gdemetri@partners.org  
 George Demetri, MD, PhD

**Johns Hopkins Sidney Kimmel Comp Cancer Center**  
 Baltimore, MD USA  
 Margaret Fogle  
 410-955-7349  
 mfogel@jhmi.edu  
 Susan Huddock  
 410-502-1036  
 shuddock@jhmi.edu  
 Katherine Thornton, MD

**University of Michigan**  
 Ann Arbor, MI USA  
 Gino Metko  
 734-647-2095  
 minom@umich.edu  
 Rivka Siden  
 734-936-8210  
 sidenr@umich.edu  
 Scott Schuetze, MD

**Regional Cancer center University of Ottawa**  
 Ottawa, Ontario Canada  
 Tim Asmis, MD  
 613-737-7700 ext 79556  
 Tim Asmis, MD

**University of Pennsylvania**  
 Philadelphia, PA USA  
 Robin Holmes  
 215-615-0360  
 robin.holmes@uphs.upenn.edu  
 Lauren Mennine  
 215-349-8913  
 lauren.mennine@uphs.upenn.edu  
 Weijing Sun, MD

**University of Pittsburgh Cancer Center**  
 Pittsburgh, PA USA  
 Amy Schmotzer  
 412-647-6468  
 schmotzerar@upmc.edu  
 Nathan Bahary, MD

**St. Luke's Hospital & Health Network**  
 Bethlehem, PA USA  
 Sanjiv Agarwala, MD  
 610-954-6013  
 agarwas@slhn.org  
 Sanjiv Agarwala, MD

**Maisonneuve-Rosemont Hospital**  
 Montreal, QC Canada  
 Lucas Sideris, MD  
 514-252-3489  
 Lucas Sideris, MD

**MD Anderson Cancer Center**  
 Houston, TX USA  
 Diane Gravel  
 713-563-6702  
 dgravel@mdanderson.org  
 Vu Ta  
 713-792-2848  
 Jon Trent, MD, PhD

**Simmons Cancer Center Univ. of Texas SW Medical Center**  
 Dallas, TX USA  
 Shelly Sherida  
 214-648-7094  
 Shelly.  
 sheridan@utsouthwestern.edu  
 Deni von Merveldt  
 214 648 5107  
 Dendra.  
 vonmerveldt@utsouthwestern.edu

**Parkland Health & Hospital System**  
 Dallas, TX USA  
 Yull Arriaga, MD  
 214-648-4180  
 Yull.  
 Arriaga@utsouthwestern.edu  
 Yull Arriaga, MD

**Oncology Alliance**  
 Wauwatosa, WI USA  
 She-ree Beekman  
 414-778-4347  
 sbeekman@oncologyalliance.com  
 Rachel Davis  
 414-778-4347  
 rdavis@oncologyalliance.com  
 Jonathan S. Maul, MD

## Dasatinib (BMS-354825)

*Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors*

Phase: 2  
 Stage: First-line  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT/PDGFR inhibitor + SRC inhibitor  
 Strategy: Block KIT + Block KIT Signal Path  
 NCT #: [NCT00568750](#)  
 Contact: Centre Hospitalier Universitaire Vaudois  
 Lausanne, Switzerland, CH -1011  
 41-21-314-0150  
**Centre Hospitalier Universitaire Vaudois**  
 Lausanne, Switzerland  
 41-21-314-0150  
 Michael Montemurro, MD

## Nilotinib

*Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)*

Phase: 2  
 Stage: First-line  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT/PDGFR inhibitor  
 Strategy: Block KIT  
 NCT #: [NCT00756509](#)  
 Contact: + 41 61 324 1111  
**Site name unknown, Bad Saarow**  
 Bad Saarow, Germany

## Treatment Stage: Gleevec-resistant

### Sunitinib

*Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant*

Phase: 4  
 Stage: Gleevec-resistant  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT/PDGFR inhibitor  
 Strategy: Block KIT  
 NCT #: [NCT00793871](#)  
 Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753  
 PfizerCancerTrials@emergingmed.com  
 Pfizer CT.gov Call Center 1-800-718-1021  
 1-877-369-9753

**Site name unknown Beijing 100035**  
 Beijing, China

**Site name unknown Beijing 100071**  
 Beijing, China

**Site name unknown, Beijing 100021**  
 Beijing, China

**Site name unknown, Nanjing 210002**  
 Nanjing, Jiangsu China

### Sunitinib or Imatinib

*Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg*

Phase: 3  
 Stage: Gleevec-resistant  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT/PDGFR inhibitor  
 Strategy: Block KIT  
 NCT #: [NCT00372567](#)  
 Contact: Pfizer Oncology Clinical Trial Information Service  
 1-877-369-9753  
 PfizerCancerTrials@emergingmed.com  
 1-800-718-1021  
 1-877-369-9753  
[PfizerCancerTrials@emergingmed.com](#)

**Site name unknown, Hamburg 22767**  
 Hamburg, Germany

**Istituto Nazionale Dei Tumori**  
 Milan, Italy  
 Paolo Casali MD

**Site name unknown, Bologna 40138**  
 Bologna, Italy

**Site name unknown, Seoul 135-710**  
 Seoul, Republic of Korea

**Site name unknown, Seoul 138-736**  
 Seoul, Republic of Korea

**Site name unknown, Barcelona 08036**  
 Barcelona, Spain

**Site name unknown, Valencia 46009**  
 Valencia, Spain

**Royal Marsden Hospital**  
 London, UK



**Southwest German Cancer Center at Eberhard-Karls University**

Tuebingen, Germany  
49-707-1298-2127  
joerg.hartmann@med.uni-tuebingen.de  
Joerg T. Hartmann, MD

**Site name unknown, Mannheim**

Mannheim, Germany

**Site name unknown, Goettingen 37075**

Goettingen, Germany

**Site name unknown, Glasgow G12 0YH**

Glasgow, UK

**Site name unknown, London NW1 2PG**

London, UK

**Site name unknown, Seoul 110-744**

Seoul, Republic of Korea

**Site name unknown, London W1**

London, UK

**Site name unknown, San Giovanni Rotondo 71013**

San Giovanni Rotondo, Foggia Italy

**Evanston Hospital**

Evanston, IL USA  
Bruce Brockstein, MD

**Glenbrook Hospital**

Glenview, IL USA  
Bruce Brockstein, MD

**Highland Park Hospital**

Highland Park, IL USA  
Bruce Brockstein, MD

**Site name unknown, Lai Chi Kok 0**

Lai Chi Kok, Kowloon Hong Kong SAR

**Christie Hospital NHS Trust**

Manchester, Lancashire UK

**Karmanos Cancer Institute**

Detroit, MI USA  
all (800) KARMANOS (1-800-527-6266) or e-mail info@karmanos.org  
Anthony Shields, MD

**Site name unknown, Farmington Hills 48334**

Farmington Hills, MI USA

**Siteman Cancer Center, Creve Coeur**

Creve Coeur, MO USA

**Washington University**

St. Louis, MO USA

**Siteman Cancer Center, St. Peters**

St. Peters, MO USA

**Site name unknown, Tuen Mun 0**

Tuen Mun, New Territories Hong Kong SAR

**Site name unknown, Henderson 89074**

Henderson, NV USA

**Site name unknown, Las Vegas 89102**

Las Vegas, NV USA

**Site name unknown, Las Vegas 89106**

Las Vegas, NV USA

**Site name unknown, Las Vegas 89148**

Las Vegas, NV USA

**New York Presbyterian Hospital - Columbia University Medical Center**

New York, NY USA  
Robert Taub, MD

**Cleveland Clinic Taussig Cancer Center**

Cleveland, OH USA

**Fox Chase Cancer Center**

Philadelphia, PA USA  
1-888-FOX-CHASE  
Margaret von Mehren, M.D.

**BIIB021 (CNF2024)**

*An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: [NCT00618319](#)  
Contact: Biogen Idec

[oncologyclinicaltrials@biogenidec.com](mailto:oncologyclinicaltrials@biogenidec.com)

**Site name unknown, Rochester**  
Rochester, MN USA

**Memorial Sloan-Kettering Cancer Center**  
New York, NY USA  
Robert Maki, MD

**Imatinib + RAD001**

*Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastrointestinal Stromal Tumors (GIST)*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR inhibitor  
Strategy: Block KIT  
Block KIT Signal Path  
NCT #: [NCT00510354](#)  
Contact: Novartis Basel  
41 61 324 1111

**Site name unknown, Bad Saarow**  
Bad Saarow, Germany

**Site name unknown, Koln**  
Koln, Germany

**Site name unknown, Dusseldorf**  
Dusseldorf, Germany

**Site name unknown, Frankfurt**  
Frankfurt, Germany

**Site name unknown, Mannheim**  
Mannheim, Germany

**Site name unknown, Munchen**  
Munchen, Germany

**Site name unknown, Tubingen**  
Tubingen, Germany

**Site name unknown, Essen**  
Essen, Germany

**Site name unknown, Hannover**  
Hannover, Germany

## Nilotinib

*Efficacy and Safety of AMN107 in Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR $\alpha$  inhibitor  
Strategy: Block KIT  
NCT #: [NCT00718562](#)  
Contact: Novartis Japan 81 3 3797 8748  
Novartis US 862 -778-8330

**Hokkaido University Hospital**  
Hokkaido, Japan

**Site name unknown, Niigata**  
Niigata, Japan

**National Cancer center Hospital East**  
Chiba, Japan

**Site name unknown, Tokyo**  
Tokyo, Japan

**Site name unknown, Kyushu**  
Kyushu, Japan

**Aichi Cancer center Hospital**  
Aichi, Japan

**Site name unknown, Osaka**  
Osaka, Japan

**Shizouka Cancer Center**  
Shizuoka, Japan

## Nilotinib

*Nilotinib in Advanced GIST*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR $\alpha$  inhibitor  
Strategy: Block KIT  
NCT #: [NCT00782834](#)  
Contact: FOX CHASE  
1-888-FOX-CHASE (369)  
**Fox Chase Cancer Center**  
Philadelphia, PA USA  
1-888-FOX-CHASE  
Margaret von Mehren, M.D.

## Nilotinib

*Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR $\alpha$  inhibitor  
Strategy: Block KIT  
NCT #: [NCT00633295](#)  
Contact: Novartis Basel  
41 61 324 1111  
**Site name unknown, Tel Aviv**  
Tel Aviv, Israel

**Site name unknown, Tel Hashomer**  
Tel Hashomer, Israel

## Sorafenib (Nexavar, BAY 43-9006)

*Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR $\alpha$  inhibitor+ VEGF inhibitor (TKI) + RAF inhibitor  
Strategy: Block KIT + Block KIT Signal Path  
NCT #: [NCT00265798](#)  
Contact: Clinical Trials Office - University of Chicago Cancer Research  
773-834-7424

**City of Hope**  
Duarte, CA USA  
Warren A. Chow, MD, (866) 434-4673 xt 64215  
Warren A. Chow, MD

**USC-Norris Cancer Center**  
Los Angeles, CA USA  
323-865-3955  
lenz@hsc.usc.edu  
Hein-Josef Lenz, M.D

**UC-Davis**  
Sacramento, CA USA  
916-734-3771  
David Gandara, MD

**University of Chicago**  
Chicago, IL USA  
Clinical Trials Office, 773 -834-7424  
Hedy Kindler, MD

**Illinois CancerCare**  
Peoria, IL USA  
John Kugler, MD, (309) 243 -3605  
John Kugler, MD

**Cancer Care Specialists**  
Decatur, IL USA  
James Wade III, MD, 217 -876-6617,  
jlwade3@sbcglobal.net  
James Wade III, MD

**Central Illinois Hem/Onc**  
Springfield, IL USA  
217-525-2500  
Edem Agamah, MD

**University of Michigan**  
Ann Arbor, MI USA  
734 647-8925  
Scott Schuetze, MD

**Memorial Sloan-Kettering Cancer Center**  
New York, NY USA  
David D'Adamo, MD, PhD,  
212-639-7573  
David D'Adamo, MD, PhD

**Medical College of Wisconsin**  
Milwaukee, WI USA  
414 805-4603  
Stuart Wong, MD

## Imatinib + Sunitinib

*Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR inhibitor  
Strategy: Block KIT  
NCT #: [NCT00573404](#)  
Contact: Cancer Information Program  
800-811-8480

**Vanderbilt-Ingram Cancer Center-Cool Springs**  
Franklin, TN USA  
615 343-4128  
Jordan Berlin

**Vanderbilt-Ingram Cancer Center at Franklin**  
Franklin, TN USA  
615 343-4128  
Jordan Berlin

**Vanderbilt-Ingram Cancer Center**  
Nashville, TN USA  
800 811-8480  
Clinical Trials Office

## *Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors*

Phase: 4  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: VEGFR inhibitor (TKI)  
Strategy: Block tumor blood vessel growth  
NCT #: [NCT00777504](#)  
Contact: C.M.L. van Herpen, Md, PhD  
31 24 3610353  
[vanherpen@onco.umcn.nl](mailto:vanherpen@onco.umcn.nl)  
**University Medical Center Nijmegen st Raboud**  
Nijmegen, Gelderland  
Netherlands  
Contact: C.M.L. van Herpen, Md, Phd 31 24 3610353  
[c.vanherpen@onco.umcn.nl](mailto:c.vanherpen@onco.umcn.nl)  
C.M.L van Herpen, Md, Phd

## Dasatinib (BMS-354825)

*Trial of Dasatinib in Advanced Sarcomas*

Phase: 2  
Stage: Gleevec-resistant  
Conditions: Gastrointestinal Stromal Tumor  
Drug Type: KIT/PDGFR inhibitor + SRC inhibitor  
Strategy: Block KIT + Block KIT Signal Path  
NCT #: [NCT00464620](#)  
Contact: Kathleen Granlund  
734-930-7607  
[kegranlund@sarctrials.org](mailto:kegranlund@sarctrials.org)  
734-930-7607  
[kegranlund@sarctrials.org](mailto:kegranlund@sarctrials.org)

**Arkansas Children's Hospital**  
Little Rock, AR USA  
Bryce Warren  
[WarrenBryceA@uams.edu](mailto:WarrenBryceA@uams.edu)  
Kimo Stine

**Stanford Cancer Center**  
Palo Alto, CA USA  
Marti Lohman  
650-725-6413  
[mlohman@stanford.edu](mailto:mlohman@stanford.edu)

Kristen Ganjoo, MD

**City of Hope**  
Duarte, CA USA  
Neeti Arora  
626-256-4673 ext. 63019  
[NArora@coh.org](mailto:NArora@coh.org)  
Warren Chow, MD

**Cedars-Sinai Outpatient Cancer Center**  
Los Angeles, CA USA  
Chi Vu  
310-423-2133  
[CVu@csocc.com](mailto:CVu@csocc.com)  
Charles Forscher, MD

**Sarcoma Oncology Center**  
Santa Monica, CA USA  
Viky Chua  
(310) 552-9999  
[vikychua@aol.com](mailto:vikychua@aol.com)  
Sant Chawla, MD

**Washington Cancer Institute**  
Washington, DC USA  
Christina Sheeran,  
202 877-5371  
[christina.m.sheeran@medstar.net](mailto:christina.m.sheeran@medstar.net)  
Dennis A. Priebat, MD

**University of Iowa Hospitals and Clinics**  
Iowa City, IA USA  
Melanie Frees, RN  
319-356-1228  
[melanie-frees@uiowa.edu](mailto:melanie-frees@uiowa.edu)  
Mohammed Milhem, MD

**Kootenai Cancer Center**  
Coeur d'Alene, ID USA  
Sheryl Gordon  
208-666-2093  
[sgolden@kmc.org](mailto:sgolden@kmc.org)  
Brian Samuels, MD

**Oncology Specialists, Park Ridge**  
Park Ridge, IL USA  
Kathy Tolzien  
847-268-8569  
[ktolzien@oncmcd.net](mailto:ktolzien@oncmcd.net)  
Pamela kaiser

**Indiana University Simon Cancer Center**  
Indianapolis, IN USA  
Kristen Potter, MS  
317-278-6616  
[krpotter@iupui.edu](mailto:krpotter@iupui.edu)  
Daniel Rushing, MD

**Massachusetts General Hospital**

Charlestown, MA USA  
 Anthony Thomas  
 617-643-5411  
 athomas2@partners.org  
 Edwin Choy, MD

**Dana Farber Cancer Institute**

Boston, MA USA  
 Sarah Solomon  
 617-582-7503  
 ssolomon1@partners.org  
 James Butrynski, MD

**Johns Hopkins Sidney Kimmel Comp Cancer Center**

Baltimore, MD USA  
 Adult Oncology, 410-955-8804  
 Pediatric Oncology, 410-955-8751  
 David Loeb, MD, PhD

**University of Michigan**

Ann Arbor, MI USA  
 Gino Metko  
 734-647-2095  
 ginom@med.umich.edu  
 Scott Schuetze, MD, PhD

**Nebraska Methodist Hospital**

Omaha, NB USA  
 Gladys Pierce  
 402-354-5129  
 gladys.peirce@nmhs.org  
 Kirsten Leu, MD

**Pennsylvania Oncology Hematology Associates**

Philadelphia, PA USA  
 Deb Riordan, RN, BS  
 215-829-6712  
 debbieriordan@pennoncology.com  
 Arthur Staddon, MD

**Fox Chase Cancer Center**

Philadelphia, PA USA  
 1-888-FOX-CHASE  
 Margeret von Mehren, M.D.

**University of Pittsburgh Cancer Center**

Pittsburgh, PA USA  
 Lynne Frydrych  
 412-623-4036  
 frydrychlm2@upmc.edu  
 Hussein Tawbi, MD, MSc

**MD Anderson Cancer Center**

Houston, TX USA  
 Joanne Gigstad  
 715-563-0510  
 jgigstad@mdanderson.org  
 Shreyas Patel, MD

**Everolimus**

*Treatment of Patients With RAD001  
 Who Have Progressive Sarcoma*

Phase: 2  
 Stage: Gleevec-resistant  
 Conditions: Sarcoma  
 Drug Type: mTOR inhibitor  
 Strategy: Block KIT Signal Path  
 NCT #: [NCT00767819](#)  
 Contact: Novartis Basel +41 61 324  
 1111 Novartis US 862-778  
 -8300

**Site name unknown, Berlin**  
 Berlin, Germany

**Site name unknown, Munchen**  
 Munchen, Germany

**Site name unknown, Dusseldorf**  
 Dusseldorf, Germany

**Site name unknown, Mannheim**  
 Mannheim, Germany

**Doxorubicin + Flavopiridol**

*Doxorubicin and Flavopiridol in  
 Treating Patients With Metastatic or  
 Recurrent Sarcoma That Cannot Be  
 Removed By Surgery*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Gastrointestinal Stromal  
 Tumor  
 Sarcoma  
 Drug Type: Transcription inhibitor +  
 Chemotherapy  
 Strategy: Freeze the cell division cycle  
 NCT #: [NCT00098579](#)  
 Contact: David R. D'Adamo, MD,  
 PhD  
 212-639-7573  
[dadamod@mskcc.org](mailto:dadamod@mskcc.org)

**Memorial Sloan-Kettering Cancer Center**

New York, NY USA  
 David D'Adamo, MD, PhD,  
 212-639-7573.  
 David D'Adamo, MD, PhD,  
 212-639-7573.

## Imatinib + IL-2

### *Imatinib + IL-2*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: KIT inhibitor + Immune stimulate  
 Strategy: Block KIT + Stimulate the immune system  
 NCT #:  
 Contact: Dr Patricia Pautier  
 téléphone direct/standard : - / 01 42 11 42 11  
 courriel : -

Institut Gustave Roussy  
 (IGR)  
 +33 (0)1 42 11 42 10  
[lannes@igr.fr](mailto:lannes@igr.fr)

**Institut Gustave-Roussy**  
 Villejuif Cedex, France  
 Dr Patricia Pautier  
 téléphone direct/standard : - / 01 42 11 42 11  
 courriel : [pautier@igr.fr](mailto:pautier@igr.fr)  
 Laurence Zitvogel  
 Dr P. Pautier is listed as PI

## Multi-bacteria vaccine (MBV)

### *A Phase I Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Gastrointestinal Stromal Tumor  
 Drug Type: Immune stimulate  
 Strategy: Stimulate the immune system  
 NCT #: **NCT00623831**  
 Contact: Krankenhaus Nordwest  
 Frankfurt, Germany  
 Antje Neumann  
 069 7601 4161  
[neumann.antje@khnw.de](mailto:neumann.antje@khnw.de)

**Krankenhaus Nordwest**  
 Frankfurt, Germany  
 Elke Jaeger, MD

## SF1126

### *A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K)*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: PI3K inhibitor  
 Strategy: Block KIT Signal Path  
 NCT #:  
 Contact: Joyce Ingold RN MSN OCN

TGen Clinical Research Services @ SHC  
 Debi & Jerry Bisgrove Research Pavilion  
 10510 N. 92nd Street, 2nd Floor  
 480 323-1339  
[jingold@shc.org](mailto:jingold@shc.org)

**TGen Clinical Research Services**  
 Scottsdale, AZ USA  
 TGen Clinical Research Services  
 Patient Care Coordinator  
 10460 N. 92nd Street, Suite 206  
 Scottsdale, AZ 85258  
 Office 480-323-1339  
 Fax 480-323-1259  
[iingold@shc.org](mailto:iingold@shc.org)  
**Arizona Cancer Center**  
 Tucson, AZ USA  
 (520) 694-CURE(2873)  
 Daruka Mahadevan, MD, PhD

**Indiana University Simon Cancer Center**  
 Indianapolis, IN USA  
 (317) 278-6942  
[gchiorea@iupui.edu](mailto:gchiorea@iupui.edu)  
 Elena Chiorean

## AUY922

### *Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: **NCT00526045**  
 Contact: 1 800 340-6843

**Site Name unknown, Bellinzona**  
 Bellinzona, Switzerland

**David Geffen School of Medicine at UCLA**  
 Los Angeles, CA USA  
 CBritten@mednet.ucla.edu  
 310-825-5268  
 Carolyn Britten, M.D.

**Medical College of Georgia**  
 Augusta, GA USA  
 706-721-2505  
[tsamuel@mcg.edu](mailto:tsamuel@mcg.edu)  
 Thomas Samuel, M.D.

**Dana Farber Cancer Institute**  
 Boston, MA USA  
 617 632-5053  
[stephen\\_hodi@dfci.harvard.edu](mailto:stephen_hodi@dfci.harvard.edu)  
 Stephen Hodi, MD, PhD

**Washington University**  
 St. Louis, MO USA  
 800-600-3606 or  
[info@ccadmin.wustl.edu](mailto:info@ccadmin.wustl.edu)  
 Timothy Pluard, MD

**Nevada Cancer Institute**  
 Las Vegas, NV USA  
 702 822-5433  
[nvogelzang@nvcancer.org](mailto:nvogelzang@nvcancer.org)  
 Nicholas Vogelzang, MD

**Cancer Therapy and Research Center**  
 San Antonio, TX USA  
 210-562-1797  
[mmita@idd.org](mailto:mmita@idd.org)  
 Monica Mita, M.D.



**MD Anderson Cancer Center**  
Houston, TX USA  
Vassiliki  
Papadimitrakopoulou, MD  
703-792-6363  
vpapadim@mdanderson.org  
Jon Trent, MD, PhD

**BGT226**

*A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: mTOR inhibitor  
PI3K inhibitor  
Strategy: Block KIT Signal Path  
NCT #: [NCT00600275](#)  
Contact: Novartis  
800 340-6843

**Hospital Vall d'Hebron**  
Barcelona, Spain

**Dana Farber Cancer Institute**  
Boston, MA USA  
Melissa Hohos  
617 632-2201  
mhohos@partners.org  
George Demetri, MD, PhD

**Massachusetts General Hospital**  
Charlestown, MA USA  
617-726-6225  
nisaac1@partners.org  
Stephen Isakoff, MD

**Nevada Cancer Institute**  
Las Vegas, NV USA  
Dianna Tercan  
(702) 822-5483  
Lin-Chi Chen, M.D., Ph.D.

**Princess Margaret Hospital**  
Toronto, ON Canada  
Lillian Siu, M.D.

**Cancer Therapy and Research Center**  
San Antonio, TX USA  
Clinical Studies Referral Office  
Telephone: 210-450-5798  
Fax: 210-616-5844  
E-mail: [onctrial@idd.org](mailto:onctrial@idd.org)  
Or contact Dr. Francis Giles directly at (210) 450-3838.

**MP470**

*MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Advanced Stage Solid Tumors  
Drug Type: KIT/PDGFR inhibitor  
Strategy: Block KIT  
NCT #: [NCT00504205](#)  
Contact: TGen Clinical Research Services Cancer Care Coordinator  
480-323-1255

**Virginia Piper Cancer Center**  
Scottsdale, AZ USA  
Raoul Tibes, MD, 480-323-1350  
Raoul Tibes, MD, 480-323-1350

**TGen Clinical Research Services**  
Scottsdale, AZ USA  
TGen Clinical Research Services  
Patient Care Coordinator  
10460 N. 92nd Street, Suite 206  
Scottsdale, AZ 85258  
Office 480-323-1339  
Fax 480-323-1259  
[iin@old@shc.org](mailto:iin@old@shc.org)

**South Texas Accelerated Research Therapeutics (START)**  
San Antonio, TX USA  
Anthony Tolcher, MD, (210) 593-5255  
Note: Contact number is not verified.  
Anthony Tolcher, MD

**SNX-5422**

*SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: [NCT00644072](#)  
Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center  
888-NCI-1937

**Warren Grant Magnuson Clinical Center**  
Bethesda, MD USA  
Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937  
Giuseppe Giaccone, MD, PhD

**AT13387**

*Phase I Study of HSP90 inhibitor AT13387 in solid tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: [NCT00878423](#)  
Contact: Andrew Wolanski

6176326623  
[Andrew.Wolanski@dfci.harvard.edu](mailto:Andrew.Wolanski@dfci.harvard.edu)

**Beth Israel Deaconess Medical Center**  
Boston, MA USA  
Sue Gotthardt RN, OCN  
(617) 632-9272  
Bruce Dezube M.D.

**Massachusetts General Hospital**  
Charlestown, MA USA  
Eunice Kwak, MD

**Dana Farber Cancer Institute**  
Boston, MA USA  
Geoffrey Shapiro, MD

## BAY 73-4506

*Phase I study of BAY 73-4506*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: KIT/PDGFR inhibitor  
 VEGFR inhibitor (TKI)  
 Strategy: Block KIT  
 NCT #:  
 Contact: Tracy Dufresne, RN, BSN,  
 OCN, CCRP  
 Physician Referral  
 Coordinator  
 210 593-5265  
[tracy.dufresne@start.stoh.com](mailto:tracy.dufresne@start.stoh.com)  
[start.stoh.com](http://start.stoh.com)

### South Texas Accelerated Research Therapeutics (START)

San Antonio, TX USA  
 Tracy Dufresne, RN, BSN,  
 OCN, CCRP  
 Physician Referral  
 Coordinator  
 Phone: 210-593-5265  
 Fax: 210-615-1075  
 E-mail: tracy.dufresne@start.stoh.com

### MD Anderson Cancer Center

Houston, TX USA  
 Clinical Trials Office - M.D.  
 Anderson Cancer Center,  
 713-792-3245  
 Jon Trent, MD, PhD

## BEZ235

*A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: mTOR inhibitor  
 PI3K inhibitor  
 Strategy: Block KIT Signal Path  
 NCT #: [NCT00620594](https://clinicaltrials.gov/ct2/show/study/NCT00620594)  
 Contact: Novartis  
 862-778-8300

### Nevada Cancer Institute

Las Vegas, NV USA  
 Dianna Tercan  
 (702) 822-5483  
 Wolfram Samlowski, M.D.

### Sarah Cannon Research Institute

Nashville, TN USA  
 615-329-7224  
 615-986-4347  
[hburris@tnonc.com](mailto:hburris@tnonc.com)  
 Howard A. Burris, III MD

## BIIB021 (CNF2024)

*Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: [NCT00618735](https://clinicaltrials.gov/ct2/show/study/NCT00618735)  
 Contact: Biogen Idec

[oncologyclinicaltrials@biogenidec.com](mailto:oncologyclinicaltrials@biogenidec.com)

South Texas Accelerated Research Therapeutics (START)  
 San Antonio, TX USA

## GDC-0941

*An Open-Label, Phase I, Dose-Escalation Study of PI3 Kinase Inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: PI3K inhibitor  
 Strategy: Block KIT Signal Path  
 NCT #: [NCT00876109](https://clinicaltrials.gov/ct2/show/study/NCT00876109)  
 Contact:

**Royal Marsden Hospital**  
 London, UK

### TGen Clinical Research Services

Scottsdale, AZ USA  
 Lynne Hull  
 480-323-1071  
[LHull@SHC.org](mailto:LHull@SHC.org)  
 Daniel D. Hoff, MD

### Dana Farber Cancer Institute

Boston, MA USA  
 Melissa Hohos  
 617 632-2201  
[mhohos@partners.org](mailto:mhohos@partners.org)  
 George Demetri, MD, PhD

### Karmanos Cancer Institute

Detroit, MI USA  
 Jie Zhang  
 313-576-9365  
[zhangj@karmanos.org](mailto:zhangj@karmanos.org)

**IPI-493**

*A Phase I Dose Escation Study of IPI-493*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: [NCT00724425](#)  
 Contact:

**Premier Oncology, Scottsdale**  
 Scottsdale, AZ USA  
 Patricia Shannon, RN  
 480 860-5000  
[pshannon@premiereoncology.com](mailto:pshannon@premiereoncology.com)  
 David Mendelson, M.D.

**Premier Oncology, Santa Monica**  
 Santa Monica, CA USA  
 Marilyn Mulay, NP  
 310-633-8400  
[mmulay@premiereoncology.com](mailto:mmulay@premiereoncology.com)  
 Lee Rosen M.D.

**San Deigo Pacific Oncology and Hematology Associates**  
 Encinitas, CA USA  
 Karen Brady, RN MSN  
 760-752-3340  
[kbrady@premiereoncology.com](mailto:kbrady@premiereoncology.com)  
 Richard Just, M.D.

**University of Colorado**  
 Aurora, CO USA  
 Stacy Grolnic, RN  
 720-848-0655  
[stacy.grolnic@uchsc.edu](mailto:stacy.grolnic@uchsc.edu)  
 Colin Weeks, MD, PhD

**PX-478**

*Phase I Trial of PX-478*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HIF-1 $\alpha$  inhibitor  
 Strategy: Block related tumor signal paths  
 Block tumor blood vessel  
 NCT #: [NCT00522652](#)  
 Contact:

**TGen Clinical Research Services**  
 Scottsdale, AZ USA  
 Lynne Hull  
 480-323-1071  
[lhull@shc.org](mailto:lhull@shc.org)  
 Daniel D. Hoff, MD  
**MD Anderson Cancer Center**  
 Houston, TX USA  
 Hala Abdulkadir  
 713-792-9944  
[habdulka@mdanderson.org](mailto:habdulka@mdanderson.org)  
 Roy S. Herbst, PhD

**PX-866**

*Phase I Trial of Oral PX-866*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: PI3K inhibitor  
 Strategy: Block KIT Signal Path  
 NCT #: [NCT00726583](#)  
 Contact:

**University of Colorado**  
 Aurora, CO USA  
 Sharon hecker  
 720-848-0667  
[sharon.hecker@ucdenver.edu](mailto:sharon.hecker@ucdenver.edu)  
 Antonio Jimeno, MD  
**MD Anderson Cancer Center**  
 Houston, TX USA  
 Rhonda Clement  
 713-563-3559  
[rclement@mdanderson.org](mailto:rclement@mdanderson.org)  
 Roy Herbst, MD

**R1507**

*A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: IGF1R inhibitor  
 Strategy: Block related tumor signal paths  
 NCT #: [NCT00560144](#)  
 Contact: Please reference Study ID Number: PDO\_NO21200  
 973-235-5000 or 800-526-6367 (FOR US ONLY)  
 973 235-5000

**Site name unknown, Denver 80218**  
 Denver, CO USA

**Site name unknown, Bethesda 20982**  
 Bethesda, MD USA

**Memorial Sloan-Kettering Cancer Center**  
 New York, NY USA  
 212-639-8267  
 Dr. Tanya Trippett  
**MD Anderson Cancer Center**  
 Houston, TX USA  
 800-392-1611 Patients  
 800-392-1611 Referring MD  
 Cynthia E. Herzog

**SNX-5422**

*Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: [NCT00506805](#)  
 Contact: Pfizer Oncology Clinical Trial Information 1-877-369-9753  
[PfizerCancerTrials@emergingmed.com](mailto:PfizerCancerTrials@emergingmed.com)  
 Pfizer CT.gov Call Center 1-800-718-1021  
 877-369-9753  
[PfizerCancerTrials@emergingmed.com](http://PfizerCancerTrials@emergingmed.com)

**TGen Clinical Research Services**  
 Scottsdale, AZ USA  
 Joyce Ingold RN MSN OCN  
 TGen Clinical Research Services  
 Patient Care Coordinator  
 10460 N. 92nd Street, Suite 206  
 Scottsdale, AZ 85258  
 Office 480-323-1339  
 Fax 480-323-1259

**Sarah Cannon Research Institute**  
 Nashville, TN USA  
 Jessica Gilbert  
 615 329-7238  
 Howard A. Burris, III MD

**SNX-5422**

*Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: [NCT00647764](#)  
 Contact: Pfizer Oncology Clinical Trial Information Service, 1-877-369-9753,  
[PfizerCancerTrials@emergingmed.com](mailto:PfizerCancerTrials@emergingmed.com)  
 Pfizer CT.gov Call Center, 1-800-718-1021  
 1-877-369-9753  
[PfizerCancerTrials@emergingmed.com](http://PfizerCancerTrials@emergingmed.com)

**Site name unknown, Bethesda 20982**  
 Bethesda, MD USA  
 Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753  
[PfizerCancerTrials@emergingmed.com](mailto:PfizerCancerTrials@emergingmed.com)

**Sorafenib + Vorinostat**

*Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HDAC inhibitor + KIT/PDGFR inhibitor  
 Strategy: Block KIT + Unblock cell death genes + Destroy KIT  
 NCT #: [NCT00635791](#)  
 Contact:

**University of Colorado**  
 Aurora, CO USA  
 Stacy Grolnic  
 720-848-0655  
[stacy.grolnic@uchsc.edu](mailto:stacy.grolnic@uchsc.edu)  
 David Ross Camidge MD

**STA-9090**

*Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: [NCT00687934](#)  
 Contact:

**Premier Oncology, Santa Monica**  
 Santa Monica, CA USA  
 310-633-8400  
 Lee Rosen

**US Oncology - Dayton Oncology & Hematology**  
 Kettering, OH USA  
[robert.raju@usoncology.com](mailto:robert.raju@usoncology.com)  
 (937)293-1622  
 Robert Raju

**STA-9090**

*Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: HSP90 inhibitor  
 Strategy: Destroy KIT  
 NCT #: [NCT00688116](#)  
 Contact:

**Dana Farber Cancer Institute**  
 Boston, MA USA  
 Melissa Hohos, RN,  
 617-632-2201  
 Geoffrey Shapiro, MD, PhD

**Massachusetts General Hospital**  
 Charlestown, MA USA  
 Pilar De La Roche Mur  
 617-632-5841

**Beth Israel Deaconess Medical Center**  
 Boston, MA USA  
 Pilar De La Roche Mur  
 617-632-5841

**Karmanos Cancer Institute**  
 Detroit, MI USA  
 Dr. Patricia LoRusso  
 313-576-8716

**XL147**

*Study of the Safety and  
 Pharmacokinetics of XL147 in Adults  
 With Solid Tumors*

**XL765**

*Study of the Safety and  
 Pharmacokinetics of XL765 in Adults  
 With Solid Tumors*

**Sunitinib + CP-751**

*Phase 1 Study of CP-751,871 in  
 Combination With Sunitinib in  
 Patients With Advanced Solid  
 Tumors*

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: KIT/PDGFR inhibitor +  
 IGF1R inhibitor  
 Strategy: Block KIT + Block related  
 tumor signal paths  
 NCT #: [NCT00729833](#)  
 Contact: Pfizer CT.gov Call Center  
 EmergingMed  
 800 718-1021  
[PfizerCancerTrials@emergingmed.com](mailto:PfizerCancerTrials@emergingmed.com)

**Premier Oncology, Santa Monica**

Santa Monica, CA USA  
 310 633-8400  
 Lee Rosen

**South Texas Accelerated  
 Research Therapeutics  
 (START)**

San Antonio, TX USA

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: PI3K inhibitor  
 Strategy: Block KIT Signal Path  
 NCT #: [NCT00486135](#)  
 Contact: Exelixis Contact Line  
 866-939-4041

**Hospital Vall d'Hebron**

Barcelona, Spain  
 Gemma Sala  
 +34 93 489 4158  
[gsala@vhebron.net](mailto:gsala@vhebron.net)  
 Jose Baselga, MD, PhD

**Dana Farber Cancer  
 Institute**

Boston, MA USA  
 Pilar de la Rocha Mur  
 617-632-5841  
[pilar\\_DeLaRochaMur@dfci.harvard.edu](mailto:pilar_DeLaRochaMur@dfci.harvard.edu)  
 Geoffrey Shapiro, MD

**Mary Crowley Medical  
 Research Center**

Dallas, TX USA  
 J.R. Dolan  
 214-658-1943  
 Gerald Edelman MD, PhD

Phase: 1  
 Stage: Gleevec-resistant  
 Conditions: Solid Tumors  
 Drug Type: mTOR inhibitor  
 PI3K inhibitor  
 Strategy: Block related tumor signal  
 paths  
 NCT #: [NCT00485719](#)  
 Contact: Exelixis Contact Line  
 866-939-4041

**Hospital Vall d'Hebron**

Barcelona, Spain  
 Gemma Sala +34 93 489  
 4158 [gsala@vhebron.net](mailto:gsala@vhebron.net)  
 Jose Baselga, MD, PhD

**Karmanos Cancer Institute**

Detroit, MI USA  
 Theresa Laeder 313-576  
 -9386  
 Patricia LoRusso, DO

**South Texas Accelerated  
 Research Therapeutics  
 (START)**

San Antonio, TX USA  
 Gina Mangold, MBA 210  
 -413-3594  
[gmangold@start.stoh.com](mailto:gmangold@start.stoh.com)  
 Kyriakos Papadopoulos, MD



**Treatment Stage:  
Palliative**

---

**Radiation**

*Radiation Therapy as Palliative  
Treatment of GIST (GIST-RT)*

---

Phase: 1  
Stage: Palliative  
Conditions: Gastrointestinal Stromal  
Tumor  
Drug Type: None  
Strategy: Radiation  
NCT #: [NCT00515931](#)  
Contact: Heikki Joensuu, M.D., Ph.D.  
947173208 Ext. 358  
[heikki.joensuu@hus.fi](mailto:heikki.joensuu@hus.fi)  
**Helsinki University Central  
Hospital**  
Helsinki, Finland  
Heikki Joensuu, M.D., Ph.D.  
947173208 Ext. 358  
[heikki.joensuu@hus.fi](mailto:heikki.joensuu@hus.fi)  
Heikki Joensuu, MD

---

**Sunitinib + Radiation**

*Sutent and Radiation as Treatment  
for Limited Extent Metastatic Cancer*

---

Phase: 2  
Stage: Palliative  
Conditions: Any type of Cancer  
Drug Type: KIT/PDGFR inhibitor  
Strategy: Block KIT  
NCT #: [NCT00463060](#)  
Contact: Johnny Kao, MD  
212-241-7503  
[Johnny.kao@mountsinai.org](mailto:Johnny.kao@mountsinai.org)  
**Mount Sinai School of  
Medicine**  
New York, NY USA  
212-241-7503  
[johnny.kao@mountsinai.org](mailto:johnny.kao@mountsinai.org)  
Johnny Kao, MD